<DOC>
	<DOCNO>NCT00038779</DOCNO>
	<brief_summary>The purpose study assess early treatment failure within 100 day assess effect regimen engraftment , GVHD , immune recovery , relapse malignancy survival .</brief_summary>
	<brief_title>Blood Transplantation Patients With Hematologic Malignancies Bone Marrow Failure States</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<criteria>Patients acute leukemia , lymphoma fail respond relapse chemotherapy CML beyond first chronic phase . Patients aplastic anemia myelodysplasia fail respond primary therapy eligible . Patients low grade lymphoma CLL eligible fail two chemotherapy regimen stage IV disease . Patients must &lt; age 50 related haploidentical donor ( phenotypically one , two three HLA A , B DR antigen mismatch ) donor . Patients adequate hepatic renal function bilirubin less equal 1.5mg % , SGPT le equal 3x upper limit normal , creatine less equal 1.5mg % . Patients serious intercurrent medical illness eligible . Patients donor must provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>CML</keyword>
	<keyword>CLL</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>MDS</keyword>
	<keyword>AA</keyword>
</DOC>